WO2022074621A8 - Covid-19-binding immunoglobulins and methods for their use - Google Patents

Covid-19-binding immunoglobulins and methods for their use Download PDF

Info

Publication number
WO2022074621A8
WO2022074621A8 PCT/IB2021/059246 IB2021059246W WO2022074621A8 WO 2022074621 A8 WO2022074621 A8 WO 2022074621A8 IB 2021059246 W IB2021059246 W IB 2021059246W WO 2022074621 A8 WO2022074621 A8 WO 2022074621A8
Authority
WO
WIPO (PCT)
Prior art keywords
cov
covid
sars
methods
antibodies
Prior art date
Application number
PCT/IB2021/059246
Other languages
French (fr)
Other versions
WO2022074621A1 (en
Inventor
Sachdev Sidhu
Mart Ustav
Shane MIERSCH
Zhijie Li
James Michael RINI
Original Assignee
The Governing Council Of The University Of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Governing Council Of The University Of Toronto filed Critical The Governing Council Of The University Of Toronto
Publication of WO2022074621A1 publication Critical patent/WO2022074621A1/en
Publication of WO2022074621A8 publication Critical patent/WO2022074621A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Described herein are synthetic monoclonal antibodies, built on a human IgG framework, e.g., Trastuzumab, that bind to the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete for ACE2 binding, and potently inhibit SARS-CoV-2 infection and proliferation. The antibodies that exhibit neutralization potencies at sub-nanomolar concentrations against SARS-CoV-2/USA/WA1 in Vero E6 cells are bound to the receptor binding domain (RBD).
PCT/IB2021/059246 2020-10-08 2021-10-08 Covid-19-binding immunoglobulins and methods for their use WO2022074621A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089414P 2020-10-08 2020-10-08
US63/089,414 2020-10-08

Publications (2)

Publication Number Publication Date
WO2022074621A1 WO2022074621A1 (en) 2022-04-14
WO2022074621A8 true WO2022074621A8 (en) 2022-12-29

Family

ID=81126680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/059246 WO2022074621A1 (en) 2020-10-08 2021-10-08 Covid-19-binding immunoglobulins and methods for their use

Country Status (1)

Country Link
WO (1) WO2022074621A1 (en)

Also Published As

Publication number Publication date
WO2022074621A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
RU2406730C2 (en) Humanised monoclonal ahti-cd20-antibody
EA202191580A1 (en) SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION
CY1114658T1 (en) PRIMARY ANTIGEN COMMUNICATION Binding Proteins
MA32982B1 (en) Binding proteins to human cgrp receptors
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
EP3421488A3 (en) Multispecific antigen-binding molecules and uses thereof
AR079944A1 (en) NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT
NZ591056A (en) Human cytomegalovirus neutralizing antibodies and use thereof
UA94452C2 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
EA201100546A1 (en) POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
GEP20115226B (en) P-cadherin antibodies
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
MA33387B1 (en) POLYPEPTIDES AND PROCESSING METHOD
EA200970694A1 (en) PEHYLATED Fab ANTIBODY FRAGMENTS TO Aβ PEPTIDE
WO2014200898A3 (en) Cmv neutralizing antigen binding proteins
EA201290589A1 (en) CD127-BINDING PROTEINS
EA202190608A1 (en) SINGLE DOMAIN ANTI-BCMA ANTIBODIES AND THEIR APPLICATION
CY1115349T1 (en) CXCR4 CLEANED ANTIBODIES FOR CANCER TREATMENT
EA202192294A1 (en) ANTIBODIES TO TREM2 AND METHODS FOR THEIR APPLICATION
RU2017113732A (en) AN ANTIBODY THAT HAS THE ABILITY TO NEUTRALIZE AN ACTIVITY SUBSTANCE, AN ALTERNATIVE FUNCTION OF COLLECTION FACTOR VIII (FVIII)
CY1115295T1 (en) SYNTHESIS FOR PATHOLOGY CONSULTATION WITH MSRV / HERV-W
MX2022011951A (en) Antibodies binding siglec15 and uses thereof.
UA94211C2 (en) Isolated fully human monoclonal anti-cd3 antibody
MX2023009244A (en) Antibodies targeting the spike protein of coronaviruses.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21877121

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21877121

Country of ref document: EP

Kind code of ref document: A1